Alluvi, previously BI 4744, offers a promising breakthrough in obesity treatment. This dual activator targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable results in clinical assessments, https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/